Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.

IF 2.3 4区 医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-02-03 DOI:10.1080/1750743X.2025.2455922
Paige Benson, Omar Abdel-Rahman
{"title":"Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.","authors":"Paige Benson, Omar Abdel-Rahman","doi":"10.1080/1750743X.2025.2455922","DOIUrl":null,"url":null,"abstract":"<p><p>Anaplastic and poorly differentiated thyroid carcinomas are the two most aggressive forms of thyroid cancers and carry significant morbidity and mortality despite multimodal therapeutic approaches. Anaplastic thyroid carcinoma (ATC) and, to a lesser degree, poorly differentiated thyroid carcinoma (PDTC) have a high tumor mutation burden, and immunologically hot tumor microenvironment when compared to well-differentiated thyroid carcinomas. As such, immunotherapy, and in particular immune checkpoint inhibitors, have been hypothesized to be effective against these cancers. This review aims to explore the biological rationale for immunotherapy in dedifferentiated thyroid carcinomas and to summarize the current evidence underlying this treatment modality.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"47-55"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834419/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2455922","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Anaplastic and poorly differentiated thyroid carcinomas are the two most aggressive forms of thyroid cancers and carry significant morbidity and mortality despite multimodal therapeutic approaches. Anaplastic thyroid carcinoma (ATC) and, to a lesser degree, poorly differentiated thyroid carcinoma (PDTC) have a high tumor mutation burden, and immunologically hot tumor microenvironment when compared to well-differentiated thyroid carcinomas. As such, immunotherapy, and in particular immune checkpoint inhibitors, have been hypothesized to be effective against these cancers. This review aims to explore the biological rationale for immunotherapy in dedifferentiated thyroid carcinomas and to summarize the current evidence underlying this treatment modality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探讨免疫治疗在滤泡细胞源性甲状腺癌治疗中的作用。
甲状腺无节细胞癌和分化不良甲状腺癌是甲状腺癌中最具侵袭性的两种癌症,尽管采用了多模式治疗方法,但它们的发病率和死亡率仍然很高。与分化良好的甲状腺癌相比,甲状腺无节细胞癌(ATC)和分化较差的甲状腺癌(PDTC)具有较高的肿瘤突变负荷和免疫热肿瘤微环境。因此,免疫疗法,尤其是免疫检查点抑制剂,被认为可以有效治疗这些癌症。本综述旨在探讨免疫疗法治疗甲状腺低分化癌的生物学原理,并总结这种治疗方式的现有证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Immune checkpoint inhibitors in dedifferentiated chondrosarcoma: toward breaking therapeutic resistance. Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. Evaluating pozelimab in the treatment of CHAPLE disease. Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies. Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1